Literature DB >> 30865919

Pancreatic Adenocarcinoma, Version 1.2019.

Margaret A Tempero1, Mokenge P Malafa2, E Gabriela Chiorean3, Brian Czito4, Courtney Scaife5, Amol K Narang6, Christos Fountzilas7, Brian M Wolpin8, Mahmoud Al-Hawary9, Horacio Asbun10, Stephen W Behrman11, Al B Benson12, Ellen Binder13, Dana B Cardin14, Charles Cha15, Vincent Chung16, Mary Dillhoff17, Efrat Dotan18, Cristina R Ferrone19, George Fisher20, Jeffrey Hardacre21, William G Hawkins13, Andrew H Ko1, Noelle LoConte22, Andrew M Lowy23, Cassadie Moravek24, Eric K Nakakura1, Eileen M O'Reilly25, Jorge Obando4, Sushanth Reddy26, Sarah Thayer27, Robert A Wolff28, Jennifer L Burns29, Griselda Zuccarino-Catania29.   

Abstract

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.

Entities:  

Mesh：

Year:  2019        PMID： 30865919     DOI： 10.6004/jnccn.2019.0014

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  78 in total

Review 1.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

2.  A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma.

Authors:  Edoardo Maria Muttillo; Antonio Ciardi; Paolina Saullo; Raffaele Troiano; Gabriele Masselli; Marianna Guida; Alessandra Tortora; Isabella Sperduti; Giulio Marinello; Piero Chirletti; Roberto Caronna
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?

Authors:  Eileen M O'Reilly; Cristina Ferrone
Journal:  J Clin Oncol       Date:  2020-03-02       Impact factor: 44.544

4.  Performance of CT-based radiomics in diagnosis of superior mesenteric vein resection margin in patients with pancreatic head cancer.

Authors:  Yun Bian; Hui Jiang; Chao Ma; Kai Cao; Xu Fang; Jing Li; Li Wang; Jianming Zheng; Jianping Lu
Journal:  Abdom Radiol (NY)       Date:  2020-03

5.  Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Ryutaro Higashi; Hiroto Hakamada; Masatoyo Nakajo; Kosei Maemura; Shiho Arima; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

6.  Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.

Authors:  Danielle R Heller; Norman G Nicolson; Nita Ahuja; Sajid Khan; John W Kunstman
Journal:  JAMA Surg       Date:  2020-02-19       Impact factor: 14.766

7.  Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.

Authors:  A Surinach; T Phung; O Abdul-Rahim; M Khushman
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

8.  Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution.

Authors:  Alejandro Recio-Boiles; Jessica Vondrak; Summana Veeravelli; James J Mancuso; Kathylynn Saboda; Denise J Roe; Irbaz Bin Riaz; Aaron J Scott; Emad Elquza; Ali McBride; Hani M Babiker
Journal:  Ann Pancreat Cancer       Date:  2020-03-09

9.  Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis.

Authors:  Amy E McGhee-Jez; Inna Chervoneva; Misung Yi; Amisha Ahuja; Ritu Nahar; Samik Shah; Rebecca Loh; Sarah Houtmann; Rashesh Shah; Charles J Yeo; Harish Lavu; Steven J Cohen; Dina Halegoua-DeMarzio; Atrayee Basu Mallick
Journal:  J Pancreat Cancer       Date:  2021-03-30

10.  Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.

Authors:  Yoo Jin Choi; Yoonhyeong Byun; Jae Seung Kang; Hyeong Seok Kim; Youngmin Han; Hongbeom Kim; Wooil Kwon; Do-Youn Oh; Woo Hyun Paik; Sang Hyub Lee; Ji Kon Ryu; Yong-Tae Kim; Kyungbun Lee; Haeryoung Kim; Eui Kyu Chie; Jin-Young Jang
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.